JP2017095457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017095457A5 JP2017095457A5 JP2016222861A JP2016222861A JP2017095457A5 JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5 JP 2016222861 A JP2016222861 A JP 2016222861A JP 2016222861 A JP2016222861 A JP 2016222861A JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- drug
- drug conjugate
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 8
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014017777 | 2014-01-31 | ||
| JP2014017777 | 2014-01-31 | ||
| JP2014168944 | 2014-08-22 | ||
| JP2014168944 | 2014-08-22 | ||
| JP2014227886 | 2014-11-10 | ||
| JP2014227886 | 2014-11-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016166850A Division JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003826A Division JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Division JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017095457A JP2017095457A (ja) | 2017-06-01 |
| JP2017095457A5 true JP2017095457A5 (enExample) | 2018-03-01 |
| JP6466895B2 JP6466895B2 (ja) | 2019-02-06 |
Family
ID=53756672
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016222861A Active JP6466895B2 (ja) | 2014-01-31 | 2016-11-16 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2024059913A Active JP7703727B2 (ja) | 2014-01-31 | 2024-04-03 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2025107304A Pending JP2025138756A (ja) | 2014-01-31 | 2025-06-25 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2024059913A Active JP7703727B2 (ja) | 2014-01-31 | 2024-04-03 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2025107304A Pending JP2025138756A (ja) | 2014-01-31 | 2025-06-25 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10155821B2 (enExample) |
| EP (5) | EP4464707A3 (enExample) |
| JP (10) | JP5998289B2 (enExample) |
| KR (13) | KR102606930B1 (enExample) |
| CN (2) | CN110464847B (enExample) |
| AU (3) | AU2015212265B2 (enExample) |
| BR (1) | BR112016013482B1 (enExample) |
| CA (1) | CA2928794C (enExample) |
| CY (3) | CY1121573T1 (enExample) |
| DK (3) | DK3466976T3 (enExample) |
| ES (3) | ES2727351T3 (enExample) |
| FI (1) | FI4212552T3 (enExample) |
| FR (1) | FR21C1030I2 (enExample) |
| HR (3) | HRP20190431T1 (enExample) |
| HU (4) | HUE057464T2 (enExample) |
| IL (5) | IL278891B2 (enExample) |
| LT (4) | LT3101032T (enExample) |
| MX (2) | MX375930B (enExample) |
| NL (1) | NL301117I2 (enExample) |
| NO (1) | NO2021027I1 (enExample) |
| NZ (1) | NZ719202A (enExample) |
| PH (2) | PH12020552271A1 (enExample) |
| PL (3) | PL4212552T3 (enExample) |
| PT (3) | PT4212552T (enExample) |
| RS (3) | RS58415B1 (enExample) |
| SG (2) | SG10201800210TA (enExample) |
| SI (3) | SI4212552T1 (enExample) |
| SM (3) | SMT202500030T1 (enExample) |
| TW (10) | TWI661839B (enExample) |
| WO (1) | WO2015115091A1 (enExample) |
| ZA (1) | ZA201602802B (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102498405B1 (ko) | 2012-10-11 | 2023-02-09 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| PT3088419T (pt) * | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| CA2928794C (en) * | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| WO2015155976A1 (ja) * | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| CN107922477B (zh) | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| WO2018066626A1 (ja) * | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| KR20240074000A (ko) * | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| CN108653746B (zh) * | 2017-03-29 | 2021-04-27 | 北京键凯科技股份有限公司 | 一种多载药点、高载药配基药物偶联物 |
| WO2019039483A1 (ja) | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法 |
| AU2018327171B2 (en) * | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
| JP7441165B2 (ja) * | 2018-05-28 | 2024-02-29 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 |
| TWI865337B (zh) | 2018-07-25 | 2024-12-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之有效的製造方法 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| CN110790840A (zh) * | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
| CA3108754A1 (en) | 2018-08-06 | 2020-02-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
| JP7481255B2 (ja) | 2018-08-23 | 2024-05-10 | 第一三共株式会社 | 抗体薬物複合体の感受性マーカー |
| CN118806924A (zh) | 2018-09-26 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| JP7608164B2 (ja) * | 2018-12-11 | 2025-01-06 | 第一三共株式会社 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| BR112021011894A2 (pt) * | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| CN109824759A (zh) * | 2019-03-08 | 2019-05-31 | 联宁（苏州）生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
| CA3133757A1 (en) | 2019-03-29 | 2020-10-08 | Medimmune Limited | Compounds and conjugates thereof |
| CN111686259B (zh) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
| BR112021026580A2 (pt) * | 2019-06-28 | 2022-05-03 | Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd | Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo |
| EP4032892A4 (en) * | 2019-09-18 | 2023-10-18 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | CAMPTOTHECIN DERIVATIVE AND CONJUGATE THEREOF |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| KR20220113728A (ko) | 2019-12-12 | 2022-08-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항 클라우딘 항체 약물 접합체 및 그 의약 용도 |
| CN118453897A (zh) | 2019-12-16 | 2024-08-09 | 江苏恒瑞医药股份有限公司 | 抗cea抗体-依喜替康类似物偶联物及其医药用途 |
| CN118873679A (zh) | 2020-01-22 | 2024-11-01 | 江苏恒瑞医药股份有限公司 | 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 |
| MX2022011770A (es) * | 2020-03-25 | 2022-10-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma. |
| WO2021190583A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-依喜替康类似物偶联物及其医药用途 |
| CN115103858B (zh) * | 2020-03-25 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| US12466784B2 (en) | 2020-06-12 | 2025-11-11 | Apical Molecular Biotech Co., Ltd. | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis |
| WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| CN116615248A (zh) * | 2020-06-24 | 2023-08-18 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和cdk9抑制剂的组合 |
| JP2023539715A (ja) * | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2021260579A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
| WO2022001864A1 (zh) * | 2020-06-28 | 2022-01-06 | 昆山新蕴达生物科技有限公司 | 一种抗体-药物偶联物，其制备方法及应用 |
| US20220072141A1 (en) * | 2020-07-13 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| KR102349925B1 (ko) * | 2020-07-16 | 2022-01-12 | 주식회사 피노바이오 | Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체 |
| CA3186675A1 (en) | 2020-07-20 | 2022-01-27 | Yasuki KAMAI | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
| CN119792565A (zh) * | 2020-08-13 | 2025-04-11 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
| CN116601713A (zh) | 2020-09-12 | 2023-08-15 | 阿斯利康(英国)有限公司 | 用于抗her2抗体-药物缀合物疗法的评分方法 |
| KR20220038601A (ko) * | 2020-09-15 | 2022-03-29 | 쓰촨 바이리 파마슈티칼 컴퍼니, 리미티드 | 캄토테신 약물 및 그의 항체 접합체 |
| MX2023003778A (es) | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
| WO2022074617A1 (en) | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| EP4227310A4 (en) * | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| CN113943310A (zh) * | 2020-10-12 | 2022-01-18 | 四川百利药业有限责任公司 | 一种氘代的喜树碱衍生物及其抗体药物偶联物 |
| US20230414778A1 (en) | 2020-11-11 | 2023-12-28 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY |
| TW202233249A (zh) | 2020-11-12 | 2022-09-01 | 日商第一三共股份有限公司 | 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療 |
| CN112535738B (zh) * | 2020-12-04 | 2022-09-09 | 中国科学技术大学 | 奥沙利铂偶联物及其制备方法和应用 |
| EP4265620A4 (en) * | 2020-12-11 | 2025-01-08 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Novel camptothecin derivative, composition containing same, and use thereof |
| US20240115721A1 (en) * | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| CN117015549A (zh) * | 2021-03-17 | 2023-11-07 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN116867789B (zh) * | 2021-03-31 | 2025-06-24 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| KR20240036506A (ko) * | 2021-05-07 | 2024-03-20 | 알렉소 온콜로지 인크. | 엑사테칸 유도체 및 그의 항체-약물 접합체 |
| CN113402584A (zh) * | 2021-07-06 | 2021-09-17 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| AU2022392822A1 (en) | 2021-11-18 | 2024-05-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CN116813631A (zh) | 2021-12-16 | 2023-09-29 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| AU2022429904A1 (en) | 2021-12-28 | 2024-06-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
| US20250161305A1 (en) * | 2021-12-28 | 2025-05-22 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
| KR20240165390A (ko) | 2022-03-16 | 2024-11-22 | 아스트라제네카 유케이 리미티드 | 항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법 |
| TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
| JP2025517656A (ja) | 2022-05-11 | 2025-06-10 | 第一三共株式会社 | 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ |
| CN119630428A (zh) | 2022-07-12 | 2025-03-14 | 西托姆克斯治疗公司 | Epcam免疫缀合物及其用途 |
| JP2025524992A (ja) | 2022-07-28 | 2025-08-01 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲートと二重特異性チェックポイント阻害剤との組み合わせ |
| CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| TW202415409A (zh) | 2022-08-02 | 2024-04-16 | 中國商諾納生物（蘇州）有限公司 | Msln抗體藥物複合體 |
| CN120225528A (zh) * | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| EP4653018A1 (en) | 2023-01-18 | 2025-11-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody drug conjugate as well as preparation method therefor and use thereof |
| EP4655006A2 (en) | 2023-01-25 | 2025-12-03 | Immunome, Inc. | Exatecan immunoconjugates |
| KR20250150111A (ko) * | 2023-02-23 | 2025-10-17 | 프론트라인 바이오파마(항저우) 컴퍼니 리미티드 | 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도 |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| KR20250163373A (ko) | 2023-04-11 | 2025-11-20 | 바이오레이 파마슈티컬 씨오., 엘티디. | 항-ror1 항체 및 그 약물 접합체 |
| WO2025019254A1 (en) | 2023-07-14 | 2025-01-23 | Guardant Health, Inc. | Classification of breast tumors using dna methylation from liquid biopsy |
| TW202506196A (zh) * | 2023-07-28 | 2025-02-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 含有糖皮質激素的抗體藥物偶聯物的藥物組合物 |
| CN119490559A (zh) * | 2023-08-16 | 2025-02-21 | 中山康方生物医药有限公司 | 化合物以及含有该化合物的抗体偶联药物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| WO2025054996A1 (en) * | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025088496A1 (en) | 2023-10-24 | 2025-05-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |
| WO2025120513A1 (en) | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
| WO2025176180A1 (zh) * | 2024-02-23 | 2025-08-28 | 江苏恒瑞医药股份有限公司 | 艾日布林衍生物药物偶联物用于治疗肿瘤的用途 |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| WO2025242090A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 喜树碱衍生物及其中间体的制备方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP1080732A4 (en) | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
| US6811996B1 (en) | 1998-10-30 | 2004-11-02 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| EP2977063A1 (en) | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むｄｄｓ化合物 |
| WO2002000734A1 (fr) | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
| RU2003100532A (ru) | 2000-07-13 | 2004-07-20 | Дайити Фармасьютикал Ко., Лтд. (JP) | Фармацевтические композиции, содержащие соединение соединения dds |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| KR100573565B1 (ko) | 2001-08-29 | 2006-04-25 | 주식회사 포스코 | 요철부가 형성된 실린더 링과 이 실린더 링이 결합된 맨드릴 |
| NZ533164A (en) | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| MXPA06013413A (es) | 2004-05-19 | 2007-01-23 | Medarex Inc | Enlazadores quimicos y conjugados de los mismos. |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| AU2005287404B2 (en) | 2004-07-22 | 2009-05-07 | Genentech, Inc. | HER2 antibody composition |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| MX2007008768A (es) | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
| DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
| DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| EP1942944A2 (en) | 2005-10-31 | 2008-07-16 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| SI2032606T1 (sl) | 2006-05-30 | 2014-02-28 | Genentech, Inc. | Protitelesa in imunokonjugati in njihove uporabe |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
| HUE025507T2 (en) * | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| CN102076717B (zh) | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| ES2544971T3 (es) * | 2008-05-13 | 2015-09-07 | Genentech, Inc. | Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| HRP20230487T1 (hr) | 2009-02-13 | 2023-07-21 | Immunomedics, Inc. | Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| BR112012001395A2 (pt) | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
| WO2011022474A2 (en) | 2009-08-18 | 2011-02-24 | Baker Hughes Incorporated | Method of forming polystalline diamond elements, polycrystalline diamond elements, and earth boring tools carrying such polycrystalline diamond elements |
| CA2775350A1 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
| EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| CA2798778C (en) | 2010-05-17 | 2016-01-05 | Livtech, Inc. | Anti-human trop-2 antibody having anti-tumor activity in vivo |
| WO2011146638A1 (en) | 2010-05-18 | 2011-11-24 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
| EP2593142B8 (en) * | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| US20130330350A1 (en) | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
| ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
| HK1201851A1 (en) | 2011-11-11 | 2015-09-11 | 瑞纳神经科学公司 | Antibodies specific for trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| SG11201403085PA (en) * | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| KR102498405B1 (ko) | 2012-10-11 | 2023-02-09 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| US9814784B2 (en) * | 2013-01-03 | 2017-11-14 | Celltrion, Inc. | Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| CA2928794C (en) * | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| RU2711640C2 (ru) | 2014-04-10 | 2020-01-17 | Дайити Санкио Компани, Лимитед | Конъюгат анти-her3 антитело-лекарственное средство |
-
2015
- 2015-01-28 CA CA2928794A patent/CA2928794C/en active Active
- 2015-01-28 PT PT221988215T patent/PT4212552T/pt unknown
- 2015-01-28 EP EP24202881.9A patent/EP4464707A3/en active Pending
- 2015-01-28 JP JP2015542503A patent/JP5998289B2/ja active Active
- 2015-01-28 WO PCT/JP2015/000355 patent/WO2015115091A1/ja not_active Ceased
- 2015-01-28 SM SM20250030T patent/SMT202500030T1/it unknown
- 2015-01-28 KR KR1020237024073A patent/KR102606930B1/ko active Active
- 2015-01-28 PL PL22198821.5T patent/PL4212552T3/pl unknown
- 2015-01-28 ES ES15743738T patent/ES2727351T3/es active Active
- 2015-01-28 EP EP21187152.0A patent/EP3973995A1/en not_active Withdrawn
- 2015-01-28 IL IL278891A patent/IL278891B2/en unknown
- 2015-01-28 LT LTEP15743738.5T patent/LT3101032T/lt unknown
- 2015-01-28 KR KR1020257036448A patent/KR20250162923A/ko active Pending
- 2015-01-28 HR HRP20190431TT patent/HRP20190431T1/hr unknown
- 2015-01-28 PT PT15743738T patent/PT3101032T/pt unknown
- 2015-01-28 DK DK18204861.1T patent/DK3466976T3/da active
- 2015-01-28 HU HUE18204861A patent/HUE057464T2/hu unknown
- 2015-01-28 LT LTEP18204861.1T patent/LT3466976T/lt unknown
- 2015-01-28 HU HUE15743738 patent/HUE044389T2/hu unknown
- 2015-01-28 RS RS20190280A patent/RS58415B1/sr unknown
- 2015-01-28 AU AU2015212265A patent/AU2015212265B2/en active Active
- 2015-01-28 SG SG10201800210TA patent/SG10201800210TA/en unknown
- 2015-01-28 EP EP18204861.1A patent/EP3466976B1/en active Active
- 2015-01-28 KR KR1020237040108A patent/KR102881140B1/ko active Active
- 2015-01-28 BR BR112016013482-6A patent/BR112016013482B1/pt active IP Right Grant
- 2015-01-28 NZ NZ719202A patent/NZ719202A/en unknown
- 2015-01-28 FI FIEP22198821.5T patent/FI4212552T3/fi active
- 2015-01-28 PL PL15743738T patent/PL3101032T3/pl unknown
- 2015-01-28 SI SI201532047T patent/SI4212552T1/sl unknown
- 2015-01-28 SG SG11201603960XA patent/SG11201603960XA/en unknown
- 2015-01-28 ES ES22198821T patent/ES3005311T3/es active Active
- 2015-01-28 DK DK15743738.5T patent/DK3101032T3/en active
- 2015-01-28 HU HUE22198821A patent/HUE070620T2/hu unknown
- 2015-01-28 LT LTEP22198821.5T patent/LT4212552T/lt unknown
- 2015-01-28 KR KR1020167015961A patent/KR101916553B1/ko active Active
- 2015-01-28 MX MX2016006498A patent/MX375930B/es active IP Right Grant
- 2015-01-28 HR HRP20241783TT patent/HRP20241783T1/hr unknown
- 2015-01-28 SI SI201530587T patent/SI3101032T1/sl unknown
- 2015-01-28 CN CN201910768778.XA patent/CN110464847B/zh active Active
- 2015-01-28 SM SM20190211T patent/SMT201900211T1/it unknown
- 2015-01-28 KR KR1020187031594A patent/KR102190548B1/ko active Active
- 2015-01-28 EP EP22198821.5A patent/EP4212552B1/en active Active
- 2015-01-28 KR KR1020227022459A patent/KR102465042B1/ko active Active
- 2015-01-28 ES ES18204861T patent/ES2895254T3/es active Active
- 2015-01-28 KR KR1020237008409A patent/KR102557062B1/ko active Active
- 2015-01-28 KR KR1020207035147A patent/KR102238848B1/ko active Active
- 2015-01-28 SM SM20210659T patent/SMT202100659T1/it unknown
- 2015-01-28 KR KR1020217009854A patent/KR102275925B1/ko active Active
- 2015-01-28 KR KR1020217032820A patent/KR102362920B1/ko active Active
- 2015-01-28 CN CN201580003121.4A patent/CN105829346B/zh active Active
- 2015-01-28 RS RS20211465A patent/RS62618B1/sr unknown
- 2015-01-28 DK DK22198821.5T patent/DK4212552T3/da active
- 2015-01-28 EP EP15743738.5A patent/EP3101032B1/en active Active
- 2015-01-28 KR KR1020217021044A patent/KR102314913B1/ko active Active
- 2015-01-28 SI SI201531748T patent/SI3466976T1/sl unknown
- 2015-01-28 KR KR1020227038845A patent/KR102510128B1/ko active Active
- 2015-01-28 PL PL18204861T patent/PL3466976T3/pl unknown
- 2015-01-28 RS RS20241442A patent/RS66412B1/sr unknown
- 2015-01-28 HR HRP20211848TT patent/HRP20211848T1/hr unknown
- 2015-01-28 PT PT18204861T patent/PT3466976T/pt unknown
- 2015-01-28 PH PH1/2020/552271A patent/PH12020552271A1/en unknown
- 2015-01-28 KR KR1020227004389A patent/KR102417312B1/ko active Active
- 2015-01-30 TW TW107116039A patent/TWI661839B/zh active
- 2015-01-30 TW TW111122224A patent/TWI796245B/zh active
- 2015-01-30 TW TW111122222A patent/TWI796243B/zh active
- 2015-01-30 TW TW111122225A patent/TWI796246B/zh active
- 2015-01-30 TW TW112104986A patent/TWI848560B/zh active
- 2015-01-30 TW TW113121616A patent/TWI870307B/zh active
- 2015-01-30 TW TW110104664A patent/TWI789700B/zh active
- 2015-01-30 TW TW111122223A patent/TWI796244B/zh active
- 2015-01-30 TW TW108114649A patent/TWI722422B/zh active
- 2015-01-30 TW TW104103127A patent/TWI627967B/zh active
-
2016
- 2016-04-21 IL IL245252A patent/IL245252B/en active IP Right Grant
- 2016-04-22 ZA ZA2016/02802A patent/ZA201602802B/en unknown
- 2016-05-16 PH PH12016500904A patent/PH12016500904A1/en unknown
- 2016-05-18 MX MX2020010682A patent/MX2020010682A/es unknown
- 2016-07-28 US US15/221,851 patent/US10155821B2/en active Active
- 2016-08-29 JP JP2016166850A patent/JP6046301B1/ja active Active
- 2016-11-16 JP JP2016222861A patent/JP6466895B2/ja active Active
-
2017
- 2017-01-13 JP JP2017003826A patent/JP6105183B1/ja active Active
-
2018
- 2018-09-13 US US16/130,615 patent/US11795236B2/en active Active
-
2019
- 2019-01-10 JP JP2019002311A patent/JP6665325B2/ja active Active
- 2019-04-11 CY CY20191100406T patent/CY1121573T1/el unknown
- 2019-05-21 IL IL266790A patent/IL266790A/en active IP Right Grant
-
2020
- 2020-01-29 AU AU2020200596A patent/AU2020200596B2/en active Active
- 2020-02-19 JP JP2020025886A patent/JP6914380B2/ja active Active
- 2020-08-19 US US16/997,613 patent/US11584800B2/en active Active
-
2021
- 2021-07-06 HU HUS2100025C patent/HUS2100025I1/hu unknown
- 2021-07-06 NO NO2021027C patent/NO2021027I1/no unknown
- 2021-07-07 CY CY2021018C patent/CY2021018I2/el unknown
- 2021-07-12 FR FR21C1030C patent/FR21C1030I2/fr active Active
- 2021-07-13 LT LTPA2021515C patent/LTC3101032I2/lt unknown
- 2021-07-13 JP JP2021115436A patent/JP7146031B2/ja active Active
- 2021-07-16 NL NL301117C patent/NL301117I2/nl unknown
- 2021-11-30 CY CY20211101037T patent/CY1124774T1/el unknown
-
2022
- 2022-06-02 AU AU2022203818A patent/AU2022203818A1/en active Pending
- 2022-09-20 JP JP2022149242A patent/JP7467557B2/ja active Active
-
2023
- 2023-09-12 US US18/367,446 patent/US20240026030A1/en active Pending
-
2024
- 2024-01-29 IL IL310627A patent/IL310627B1/en unknown
- 2024-04-03 JP JP2024059913A patent/JP7703727B2/ja active Active
-
2025
- 2025-06-25 JP JP2025107304A patent/JP2025138756A/ja active Pending
- 2025-10-29 IL IL324322A patent/IL324322A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017095457A5 (enExample) | ||
| HRP20241783T1 (hr) | Anti-her2 antitijelo-lijek konjugat | |
| JP2015508074A5 (enExample) | ||
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| JPWO2020027100A5 (enExample) | ||
| JP2018504379A5 (enExample) | ||
| HRP20210593T1 (hr) | Anti-her3 antitijelo-lijek konjugat | |
| JP2014528480A5 (enExample) | ||
| JPWO2020059772A5 (enExample) | ||
| JP2021503450A5 (enExample) | ||
| JP2013166763A5 (enExample) | ||
| JP2020526584A5 (enExample) | ||
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2019501204A5 (enExample) | ||
| JP2017536340A5 (enExample) | ||
| JP2018508572A5 (enExample) | ||
| FI3345613T3 (fi) | Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin | |
| HRP20211164T1 (hr) | Derivati hemiasterlina za konjugaciju i terapiju | |
| JP2017536344A5 (enExample) | ||
| HRP20140627T1 (hr) | Kristalna monotosilatna sol od 2-metil-2-[4-(3-metil-2-okso-8-kinolin-3-il-2,3-dihidro-imidazo[4,5-c]kinolin-1-il)-fenil]-propionitrila | |
| TR201802090T4 (tr) | Kanserin tedavisine yönelik monoklonal anti-GT468 antikorlar. | |
| IL273387B1 (en) | Thylanstatin analogs | |
| JP2021503915A5 (enExample) | ||
| JPWO2021055295A5 (enExample) |